Literature DB >> 28342065

Pharmacokinetics of linezolid in plasma and cerebrospinal fluid in patients with cerebral hemorrhage post-surgical intervention.

Yan Tang1, Lingti Kong2, Chenchen Wu3, Xiaohua Zhang1, Guoyu Lu1, Xiaofei Wu4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28342065     DOI： 10.1007/s00228-017-2239-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

Review 1.  [Linezolid, the first oxazolidinone antibiotic].

Authors:  H Dutronc; F Bocquentin; T Galpérine; S Lafarie-Castet; M Dupon
Journal:  Med Mal Infect       Date:  2005-11-16       Impact factor: 2.152

2.  Ventriculostomy-associated infections: incidence and risk factors.

Authors:  Yaseen Arabi; Ziad A Memish; Hanan H Balkhy; Christine Francis; Ahmad Ferayan; Abdullah Al Shimemeri; Maha A Almuneef
Journal:  Am J Infect Control       Date:  2005-04       Impact factor: 2.918

3.  Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.

Authors:  Piergiorgio Cojutti; Natalia Maximova; Giovanni Crichiutti; Miriam Isola; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2014-09-01       Impact factor: 5.790

4.  Linezolid-induced inhibition of mitochondrial protein synthesis.

Authors:  An S De Vriese; Rudy Van Coster; Joel Smet; Sara Seneca; Andrew Lovering; Lindsey L Van Haute; Ludo J Vanopdenbosch; Jean-Jacques Martin; Chantal Ceuterick-de Groote; Stefaan Vandecasteele; Johan R Boelaert
Journal:  Clin Infect Dis       Date:  2006-03-13       Impact factor: 9.079

5.  Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.

Authors:  P Kloss; L Xiong; D L Shinabarger; A S Mankin
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

Review 6.  Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome.

Authors:  K Z Vardakas; I Kioumis; M E Falagas
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 7.  Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Authors:  Matthew E Falagas; Konstantinos Z Vardakas
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.

Authors:  S Luque; S Grau; F Alvarez-Lerma; O Ferrández; N Campillo; J P Horcajada; M Basas; J Lipman; J A Roberts
Journal:  Int J Antimicrob Agents       Date:  2014-08-20       Impact factor: 5.283

9.  Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid.

Authors:  A T Kessler; A P Kourtis
Journal:  Infection       Date:  2007-07-23       Impact factor: 3.553

10.  The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections.

Authors:  Jinjian Fu; Xiaohua Ye; Cha Chen; Sidong Chen
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240
View more
  1 in total

1.  Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance.

Authors:  Pier Giorgio Cojutti; Cristina Barbarino; Amato De Monte; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-04-29       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.